Supplemental Data:

Opposing Nodal/Vg1 and BMP signals mediate axial patterning in embryos of the basal chordate amphioxus

T. Onai, J.-K. Yu, I. L. Blitz, K. W. Y. Cho, L. Z. Holland





Fig. S2. Conserved synteny of *Cerberus* in amphioxus (*Branchiostoma floridae*), *Xenopus tropicalis* and human (*Homo sapiens*). In the two vertebrates, *Cerberus-1* is located on the same scaffold/chromosome as *zdhhc21* and *nfib*. Similarly in amphioxus, *Cerberus* is on the same scaffold as the other two genes, although there have been some gene rearrangements. This conserved synteny indicates that the amphioxus gene we have identified as *Cerberus* is probably a true homolog of vertebrate *Cerberus* genes even though gene sequences are sufficiently diverged that bootstrap support is low in phylogenetic analyses (Fig. S1).







Figure S6. In vitro translation demonstrates that MOs effectively block translation. Control lanes at left included the pCS2 vector, no MO. Second lanes from left, plasmid but no MO. Third lanes from left plasmid plus gene-specific MO. Fourth lanes from left, plasmid plus control MO. A) Amphioxus Blimp1 MO. B) Amphioxus *Chordin* morpholino-A. C) Amphioxus *Chordin* MO-B. morpholino . In vitro tanslation for the *pCS2Amphichd-myc* and *pCS2Amphiblimp-myc* plasmids was with the TNT SP6 Quick Coupled Transcription/Translation System (Promega Inc., Fitchburg, WI, USA). Samples separated on SDS-polyacrylamide gels were subjected to western blotting and probed with an anti-myc antibody (Roche Molecular Biochemicals, Indianapolis, IN, USA at a 1:1000 dilution. Detection was with the Amersham ECL PLUSTM Western Blotting Detection Reagents (GE Healthcare, Piscataway, NJ, USA).



The numbers of embryos injected and the percentage expressing a particular phenotype for each treatment are listed below for each text figure.

Fig2. Human activin protein was added to about 200 embryos for each of 3 egg batches. More than 80% had the expanded head expanded phenotype at the neurula stage. For gastrula stage embryos, the phenotypes are representative ones. Ten or more embryos per probe were assayed and more than 80% showed the representative phenotype.

Fig3. For gastrula phenotypes, more than 100 embryos per batch were treated with SB505124. At least 10 embryos for each probe were analyzed. The phenotypes showed in the figures are representative of more than 90% of the embryos. For neurula stage phenotypes, about 200-300 embryos per batch were treated with SB505124. Over 90% showed the representative phenotype.

Fig4. We injected more than 100 embryos per batch for each of 4 egg batches with $1.0\mu g/\mu l$ BMP2/4 mRNA. Only strongly fluorescence embryos were assayed. The neurula phenotypes shown are characteristic of more than 60% of the embryos assayed. For the figure 4 I-K the numbers of embryos are I (100% n=10), J (100% n=15), K (66% n=21)

Fig5. We injected 1.0 mM chdMOA into more than 100 embryos/each of 10 batches and isolated only strongly fluorescent embryos. The phenotypes shown for neurula to larva are representative of more than 60% of the embryos assayed. For gastrula fixed embryos, we analyzed the embryos

10-15 embryos/probes and the phenotypes are representative of more than 80% of the embryos assayed.

Fig6. We injected $1.0\mu g/\mu l$ Cerberus mRNA into more than 100 embryos/batch for 2 times and isolated only strongly fluorescence embryos. The neurula phenotypes are representative of more than 60% of embryos assayed. We injected 1.0mM blimp1 MO into more than 100 embryos/batch for 4 times and isolated only strongly fluorescence embryos. The phenotypes are representative of more than 60% of embryos assayed.

Fig7 For *Xenopus* injections, the numbers of the embryos are A (100% n=10), B (37% n=8), C (100% n=12), D (100% n=8), E (100% n=12), F (100% n=14)